Form4insider filings, from the source

SEC Form 4 · accession 0000899243-18-015796

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — President and CEO · Director
Period of report
Jun 6, 2018
Accepted (ET)
Jun 8, 2018 · 5:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueJun 6, 2018M30,465$3.0221A345,773D
Common Stock, $0.0001 par valueF2Jun 6, 2018S30,465$31.1955D315,308D
Common Stock, $0.0001 par valueJun 7, 2018M32,598$3.0221A347,906D
Common Stock, $0.0001 par valueF3Jun 7, 2018S32,098$30.9465D315,808D
Common Stock, $0.0001 par valueJun 7, 2018S500$31.58D315,308D
Common Stock, $0.0001 par valueJun 8, 2018M42,106$3.0221A357,414D
Common Stock, $0.0001 par valueF4Jun 8, 2018S42,106$30.6966D315,308D
Common Stock, $0.0001 par valueF5holding———12,009IBy GRAT 2
Common Stock, $0.0001 par valueF6holding———12,009IBy Wife's GRAT 2
Common Stock, $0.0001 par valueF7holding———25,532IBy Family Trust
Common Stock, $0.0001 par valueF8holding———41,075IBy Child's Trust 1
Common Stock, $0.0001 par valueF9holding———41,075IBy Child's Trust 2

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F10$3.0221Jun 6, 2018M30,465D—May 18, 2025Common Stock30,465400,103D
Stock Option (right to buy)F10$3.0221Jun 7, 2018M32,598D—May 18, 2025Common Stock32,598367,505D
Stock Option (right to buy)F10$3.0221Jun 8, 2018M42,106D—May 18, 2025Common Stock42,106325,399D

Explanation of responses